scholarly journals Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment

1999 ◽  
Vol 14 (8) ◽  
pp. 2050-2051 ◽  
Author(s):  
D. Kuypers ◽  
J. Vanwalleghem ◽  
B. Maes ◽  
T. Messiaen ◽  
Y. Vanrenterghem ◽  
...  
Keyword(s):  
Chronic Hemodialysis ◽  
Serum Concentrations ◽  
Hemodialysis Treatment

Lack of Oxidative Damage in Serum Polyunsaturated Fatty Acids before and after Dialysis in Chronic Uremic Patients

1989 ◽  
Vol 12 (8) ◽  
pp. 515-518 ◽  
Author(s):  
M. Taccone-Gallucci ◽  
R. Lubrano ◽  
A. Belli ◽  
G. Citti ◽  
M. Morosetti ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Oxidative Damage ◽  
Polyunsaturated Fatty Acids ◽  
Fatty Acid Pattern ◽  
Chronic Hemodialysis ◽  
Serum Concentrations ◽  
Serum Fatty Acid ◽  
Before And After ◽  
Uremic Patients ◽  
Mononuclear Blood Cells

We described previously that in the erythrocytes and mononuclear blood cells from uremic patients on chronic hemodialysis, the membrane concentrations of malonyldialdehyde (MDA), resulting from peroxidation of polyunsaturated fatty acids (PUFA) in the membrane itself increased, and the concentrations of vitamin E (VIT E), the major antioxidizing agent, were lower. In the present study we analysed whether similar oxidative damage is seen in the serum from hemodialysis patients and whether the serum fatty acid pattern is affected. No evidence was found of oxidative damage in the serum during hemodialysis, serum concentrations of MDA and VIT E remaining constant before and after dialysis. No change was observed in serum pattern of PUFA, particularly linoleic acid. We therefore assume that the oxidative damage described in uremic patients is mainly intracellular.

scholarly journals Immunological Effects of a Single Hemodialysis Treatment

Medicina ◽  
2020 ◽  
Vol 56 (2) ◽  
pp. 71 ◽  
Author(s):  
Andrea Angeletti ◽  
Fulvia Zappulo ◽  
Chiara Donadei ◽  
Maria Cappuccilli ◽  
Giulia Di Certo ◽  
...  
Keyword(s):  
Adaptive Response ◽  
Chronic Hemodialysis ◽  
Hemodialysis Treatment ◽  
Immune Balance ◽  
Immunological Effects ◽  
Exogenous Factors ◽  
Immune System Modulation ◽  
Stage Renal Disease ◽  
End Stage ◽  
Innovative Techniques

Immune disorders, involving both innate and adaptive response, are common in patients with end-stage renal disease under chronic hemodialysis. Endogenous and exogenous factors, such as uremic toxins and the extracorporeal treatment itself, alter the immune balance, leading to chronic inflammation and higher risk of cardiovascular events. Several studies have previously described the immune effects of chronic hemodialysis and the possibility to modulate inflammation through more biocompatible dialyzers and innovative techniques. On the other hand, very limited data are available on the possible immunological effects of a single hemodialysis treatment. In spite of the lacking information about the immunological reactivity related to a single session, there is evidence to indicate that mediators of innate and adaptive response, above all complement cascade and T cells, are implicated in immune system modulation during hemodialysis treatment. Expanding our understanding of these modulations represents a necessary basis to develop pro-tolerogenic strategies in specific conditions, like hemodialysis in septic patients or the last session prior to kidney transplant in candidates for receiving a graft.

Serum Erythropoietin Concentrations and Iron Status in Patients on Chronic Hemodialysis

1992 ◽  
Vol 38 (2) ◽  
pp. 199-203 ◽  
Author(s):  
Chuichi Seguchi ◽  
Teruo Shima ◽  
Moriharu Misaki ◽  
Yoshihiro Takarada ◽  
Toni Okazaki
Keyword(s):  
Negative Correlation ◽  
Binding Capacity ◽  
Iron Status ◽  
Geometric Mean ◽  
Normal Subjects ◽  
Significant Negative Correlation ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Serum Concentrations ◽  
Serum Erythropoietin

Abstract We studied the relationship between serum erythropoietin (EPO) concentration and iron status in 67 patients undergoing chronic hemodialysis. Serum concentrations of EPO were measured by RIA with recombinant human EPO. The geometric mean of the serum EPO concentration was 10.9 int. units/L (mean +/- SD range = 7.8 - 15.3 int. units/L) in hemodialysis patients, considerably lower than that in normal subjects (12.9 int. units/L). We found no significant correlation between concentrations of serum EPO and hemoglobin in hemodialysis patients, but found a significant negative correlation between serum concentrations of EPO and iron in hemodialysis patients. Moreover, we also found a significant positive correlation between the EPO concentration and the unsaturated iron-binding capacity (UIBC) in serum, and a significant negative correlation between the serum concentrations of EPO and ferritin in hemodialysis patients. Several patients who had relatively high EPO concentrations for hemodialysis patients also had low iron concentrations, high UIBC values, and low ferritin concentrations. These findings suggest that iron was utilized even at these EPO concentrations, which were very low for the degree of anemia observed in the hemodialysis patients.

Bone Marrow Amyloidosis with Erythropoietin-resistant Anemia in a Patient Undergoing Chronic Hemodialysis Treatment

2003 ◽  
Vol 96 (5) ◽  
pp. 491-493
Author(s):  
Ramazan Çetinkaya ◽  
Ali Riza Odabas ◽  
Yilmaz Selcuk ◽  
Zekai Erman ◽  
Hasan Kaya
Keyword(s):  
Bone Marrow ◽  
Chronic Hemodialysis ◽  
Hemodialysis Treatment

The Effect of Type and Vascular Access Quality on the Outcome of Chronic Hemodialysis Treatment

2010 ◽  
Vol 20 (5) ◽  
pp. S118-S121 ◽  
Author(s):  
Krzysztof Letachowicz ◽  
Wacław Weyde ◽  
Waldemar Letachowicz ◽  
Marian Klinger
Keyword(s):  
Vascular Access ◽  
Chronic Hemodialysis ◽  
Hemodialysis Treatment

Biokompatibilitätsprobleme bei der Hämodialyse

1990 ◽  
Vol 10 (02) ◽  
pp. 84-91 ◽  
Author(s):  
U. Weber ◽  
J. Lissmann ◽  
R. Bambauer
Keyword(s):  
Side Effects ◽  
Chronic Hemodialysis ◽  
Low Risk ◽  
Dialysis Fluid ◽  
Hemodialysis Treatment ◽  
Number Of Patients ◽  
Artificial Surfaces ◽  
Near Future

ZusammenfassungSeit erstmals Interaktionen von Blut und körperfremden Materialien bei der chronischen Hämodialysebehandlung beobachtet wurden, folgten zahlreiche Untersuchungen, um das Phänomen der Biokompatibilität zu ergründen. Dies hatte zur Folge, daß erhebliche Verbesserungen bei den Membranen, Schlauchsystemen, Geräten und der Behandlung selbst erzielt werden konnten. Im folgenden wird versucht, einen Überblick über die auslösenden Ursachen und die Phänomene, die durch die Interaktion von Blut mit körperfremden Oberflächen verursacht werden, aufzuzeigen.Die Probleme, die bei der Entwicklung biokompatibler Membranen vorhanden sind, scheinen in naher Zukunft noch nicht alle lösbar zu sein. Unsere ganze Sorgfalt muß daher der Hämodialysebehandlung selbst und der Verringerung ihrer möglichen Nebenwirkungen, die z.B. durch Reste von Sterilisationsmitteln, endotoxinhaltige Dialysierflüssigkeiten hervorgerufen werden können, gelten. Besonders im Hinblick darauf, daß die Zahl der Patienten, die Biomaterialien benötigen, rasch zunimmt und diese Patienten länger leben, wodurch sie den Gefahren durch die Biounverträglichkeit der Materialien länger ausgesetzt werden, sind wir alle aufgefordert, unseren Patienten eine risikoarme Hämodialyse zu ermöglichen served in the treatment of chronic hemodialysis, numerous investigations were performed to definite the phenomena of biocompatibility. As a consequence, considerable improvements in membranes, tube systems, equipments and in the treatment itself have been accomplished. The following is an attempt to demonstrate the initiating causes and the phenomena which results from the interaction of blood with artificial surfaces.The problems being encountered in the development of biocompatible membranes are not likely to all be solved in the near future. We must, therefore, concentrate all our efforts on the hemodialysis treatment itself and on the reduction of its possible side-effects which can, for example, be caused by the remnants of sterilizing agents, dialysis fluid containing endotoxin, etc. Especially in view of the fact that the number of patients requiring biomaterials is rapidly increasing and that these patients are living longer, whereby they are exposed to the dangers of bioincompatibility of the materials for a longer period of time, we are all called upon to provide low-risk hemodialysis for our patients.

Lp(a) and premature mortality during chronic hemodialysis treatment

1994 ◽  
Vol 67-68 ◽  
pp. 419-427 ◽  
Author(s):  
Michael D. Cressman ◽  
Daniel Abood ◽  
June O'Neil ◽  
Henry F. Hoff
Keyword(s):  
Premature Mortality ◽  
Chronic Hemodialysis ◽  
Hemodialysis Treatment

A scale development study: Hemodialysis comfort scale version II

2021 ◽  
pp. 174498712110418
Author(s):  
Cansu Kosar Sahin ◽  
Sezgi Cinar Pakyuz
Keyword(s):  
Factor Analysis ◽  
Item Analysis ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Measurement Tool ◽  
Study Item ◽  
Hemodialysis Treatment ◽  
Confirmatory Factor ◽  
Measuring Tool ◽  
Analysis Scale

Aim Aim of this study was to develop a valid and reliable measuring tool in order to evaluate comfort of patients receiving hemodialysis treatment. Background There has been available a scale developed to evaluate comfort of hemodialysis patients “HDCS (Hemodialysis Comfort Scale).” Due to HDCS consisted of nine items and evaluated comfort in two sub-dimensions, researchers who developed HDCS, stated that number of scale items and dimensions is not sufficient to fully evaluate comfort. Therefore, (Hemodialysis Comfort Scale Version II) HDCS-II was developed with this research and its development process were discussed in this article. Materials and Methods Sample of this methodological research was consisted of 436 chronic hemodialysis patients, treated at five hemodialysis centers between October 2018 and May 2019. In process of creation item pool, comfort theory and literature was examined. The items in the old scale were also revised and included. Thereby a new question pool of 87 items was created. This draft scale was sent for expert opinion. In validity of scale; content validity index, exploratory and confirmatory factor analysis were used. In reliability study; Item analysis, cronbach’s alpha reliability coefficient, parallel form reliability and item analysis based on upper-lower group averages were used. Results There was consistency between expert views relating to items in scale. According to exploratory factor analysis, scale consisted of six dimensions. Cronbach alpha coefficient of 26-item scale was 0.79. Alpha values of the six factor in scale were, respectively; for physical relief 0.83, for physical ease 0.71, for psychospiritual ease 0.87, for psychospiritual transcendence 0.85, for environmental transcendence 0.82, and for sociocultural ease 0.61. Conclusion HDCS-II is a 5-point likert type and consists of 26 items and 6 factors. This scale is a valid and reliable measurement tool that can be used to determine comfort of patients undergoing hemodialysis treatment.

Potentially inappropriate prescribing of drugs in elderly patients on chronic hemodialysis treatment

2018 ◽  
Vol 89 (6) ◽  
pp. 453-460 ◽  
Author(s):  
Gorana Nedin Ranković ◽  
Slobodan Janković ◽  
Radmila Veličković Radovanović ◽  
Zorica Jović ◽  
Gordana Pešić ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Inappropriate Prescribing ◽  
Chronic Hemodialysis ◽  
Potentially Inappropriate Prescribing ◽  
Hemodialysis Treatment
Sign in / Sign up

Export Citation Format

Share Document